S1 Checklist. STROBE Checklist

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract
		Title page
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found
		Abstract, page 1
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
		Introduction, paragraphs 1-2
Objectives	3	State specific objectives, including any prespecified hypotheses
		Introduction, paragraph 3
Methods		
Study design	4	Present key elements of study design early in the paper
		Materials and methods, paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
		Results, paragraph 1
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		Materials and methods, paragraph 3-5
		(*b*) For matched studies, give matching criteria and number of exposed and unexposed
		Non-matched study
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
		Materials and Methods, paragraphs 1-4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
		Materials and Methods, paragraphs 3-4
Bias	9	Describe any efforts to address potential sources of bias
		To address potential sampling bias, we recruited schistosome-negative controls from the same village and on the same day as the schistosome-positive women were enrolled, to minimise the differences between the two groups.
Study size	10	Explain how the study size was arrived at
		The study size calculation was performed for the larger study for which this cohort was recruited, described in Materials and Methods, paragraph 2. . For this study, we included all women who were included in the larger study and attended at least one follow-up.
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
		Methods, paragraph 7
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding
		Materials and methods, paragraph 7
		(*b*) Describe any methods used to examine subgroups and interactions

		(*c*) Explain how missing data were addressed
		Data in Tables 1 and 2 was complete. In Table 3, we included missing data in the category "No answer".
		(*d*) If applicable, explain how loss to follow-up was addressed
		Loss to follow-up number and reasons are reported in Results, paragraph 4
		(*e*) Describe any sensitivity analyses
		Not applicable

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		Results, paragraph 1-2
		(b) Give reasons for non-participation at each stage
		Results, paragraph 2/Fig 1
		(c) Consider use of a flow diagram
		Results, Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		Results, paragraph 3/Table 1
		(b) Indicate number of participants with missing data for each variable of interest
		Data in Tables 1 and 2 was complete. In Table 3, we included missing data in the category "No answer".
		(c) Summarise follow-up time (eg, average and total amount)
		Results, paragraph 4/Fig 2
Outcome data	15*	Report numbers of outcome events or summary measures over time
		Results, paragraphs 5-9, Fig 3, Table 2 and 3
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		Not applicable
		(*b*) Report category boundaries when continuous variables were categorized
		Results, paragraph 5
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
		Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
		Not applicable

Discussion

Key results	18	Summarise key results with reference to study objectives
		Discussion, paragraph 1-2
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
		Discussion, paragraph 6
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
		Discussion, paragraph 2-5
Generalisability	21	Discuss the generalisability (external validity) of the study results
		Discussion, paragraph 6

Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
		Entered into online submission form

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.